{
    "clinical_study": {
        "@rank": "165008", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine target dose range of buprenorphine/naloxone\n      combination tablet that provides therapeutic response in opiate addicts with low to moderate\n      dependence, and to identify appropriate initial induction dose in opiate addicts with low to\n      moderate dependence.\""
        }, 
        "brief_title": "Buprenorphine Combination Tablet Feasibility - 1", 
        "condition": "Opioid-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Opioid-Related Disorders"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Males/Females ages 21-50, opiate dependence according to DSM-IV criteria, self-reported\n        use within the last 30 days, agreeable to conditions of study and signed informed consent\n\n        Exclusion Criteria:\n\n        Psychiatric disorder that requires medication therapy, history of seizures, pregnant\n        and/or nursing women, dependence on etoh or benzodiazepines or other sedative-hypnotics,\n        acute hepatitis, other medical conditions that deem participation to be unsafe."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": "0", 
        "firstreceived_date": "September 20, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000298", 
            "org_study_id": "NIDA-09260-1", 
            "secondary_id": "P50-09260-1"
        }, 
        "intervention": {
            "intervention_name": "Buprenorphine/naloxone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Buprenorphine", 
                "Naloxone"
            ]
        }, 
        "lastchanged_date": "August 16, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90025"
                }, 
                "name": "Friends Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Buprenorphine Combination Tablet Feasibility", 
        "overall_official": {
            "affiliation": "Friends Research Institute, Inc.", 
            "last_name": "Walter Ling, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": [
            {
                "measure": "Withdrawal symptoms"
            }, 
            {
                "measure": "Opiate use"
            }, 
            {
                "measure": "Opiate craving"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000298"
        }, 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 1995", 
        "study_design": "Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 1996"
    }, 
    "geocoordinates": {
        "Friends Research Institute": "34.052 -118.244"
    }
}